553. Enterovirus D68 Illness in Hospitalized Children Less than 2 Years of Age
Session: Poster Abstract Session: Respiratory Viruses
Thursday, October 8, 2015
Room: Poster Hall
  • IDSA_Kaylaevd68_final.pdf (278.4 kB)
  • Background: Enterovirus D68 (EV-D68) is a poorly described cause of acute respiratory infection (ARI). In August 2014, clinicians at Children’s Mercy Hospital, Kansas City identified an increase in severe ARI hospitalizations, subsequently attributed to EV-D68. Since young children are at high risk for ARI-related morbidity and mortality, we characterized EV-D68 disease in children <2 years of age. 

    Methods: Children <2 years of age were identified from a larger cohort of patients aged 0-17 years hospitalized from August 1- September 15, 2014 with positive multiplex-PCR testing for enterovirus/rhinovirus (EV/RV). Specimens were retrospectively tested for EV-D68 by sequencing or PCR; results were unavailable to providers. Clinical features, management, and outcome data were obtained from medical record review using a standardized data collection form.

    Results: Of 542 children hospitalized due to EV/RV with specimens available for further testing, 182 (33%) were <2 years. 86 (46%) were EV-D68 positive and 96 (53%) were EV-D68 negative. Compared to hospitalized children with other EV/RV, EV-D68 infected children were older (13 vs 10 months, P=0.03) and more likely to have a history of cough (84% vs 68%, P=0.01) and increased work of breathing (80% vs 60%, P=0.004). They were more likely to be hypoxic (48% vs 26%, P= 0.002), wheeze (52% vs 33%, P=0.01), and have retractions (71% vs 46%, P=0.001). More EV-D68 infected children received oxygen supplementation (74% vs 48%, P<0.001), albuterol (78% vs 48%, P<0.001), and corticosteroids (61% vs 37%, P=0.001). They were more likely to be discharged with albuterol (70% vs 38%, P<0.001) and corticosteroids (40% vs 24%, P=0.02) despite no difference in history of asthma or wheeze (30% vs 23%, P=0.26). Need for intensive care management was not more common in children with EV-D68 infection (15% vs 12%, P=0.47).  

    Conclusion: EV-D68 is a cause of ARI in young children. Despite no difference in history of bronchospasm, EV-D68 hospitalized children <2 years of age were more likely to receive asthma directed therapies, despite providers being unaware of the diagnosis. Without an EV-D68 specific therapy, future trials should consider evaluation of the utility of bronchospasm directed therapies in young children with EV-D68 infection.

    Kayla Briggs, Medical Student1, Rangaraj Selvarangan, PhD2, Ferdaus Hassan, PhD2, Mary Anne Jackson, MD, FIDSA, FPIDS2 and Jennifer Schuster, MD, MSCI2, (1)University of Missouri-Kansas City School of Medicine, Kansas City, MO, (2)Children's Mercy Hospital, Kansas City, MO


    K. Briggs, None

    R. Selvarangan, None

    F. Hassan, None

    M. A. Jackson, None

    J. Schuster, None

    See more of: Respiratory Viruses
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.